Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | ATF4 | P18848 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328507 | 0.72 | ALDH1A1 (0.52) | ATF4POLBALDH1A1HPGDNPSR1 | |
| SCHEMBL19569415 | 0.72 | ATF4 (0.80) | ATF4KDM4ENPSR1 | |
| SCHEMBL28252143 | 0.70 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2C19BLMPMP22 | |
| SCHEMBL21384542 | 0.69 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2C19BLMPMP22 | |
| SCHEMBL15008841 | 0.69 | MAOB (0.51) | ALDH1A1HTTNPSR1 | |
| SCHEMBL7068289 | 0.68 | LMNA (0.59) | CYP1A2CYP3A4CYP2C19BLMPMP22 | |
| SCHEMBL15009433 | 0.68 | MEN1 (0.61) | EPHX2ALDH1A1KDM4EHPGD | |
| SCHEMBL12651143 | 0.68 | HIF1A (0.48) | EPHX2 | |
| SCHEMBL12932189 | 0.68 | EPHX2 (1.00) | EPHX2 | |
| Meclofenoxate SCHEMBL147339 | 0.67 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C19BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160038550-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH MEMORY LOSS | KINZER CRAIG E (US) | 2016-02-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0870757-B1 | Fluoro-substituted adamantane derivatives | PFIZER (US) | 2002-06-12 | — | — | EP | claimed |
| US-6174890-B1 | A SYNERGISTIC BIOLOGICAL, NEUROMETABOLIC AND CELLTROPHIC COMPOSITION COMPRISING ANTIOXIDATIVE AND -CATABOLIC STRESS (METHIONINE),-ANABOLIC DRUGS, VASODILATIVE AND NORMO-LIPIDEMIC DRUGS (NICOTINIC ACID), ENERGOACTIVE AND ANTITOXIC | RIGA DAN (RO) | 2001-01-16 | — | — | US | claimed |
| US-6057364-A | USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS | PFIZER INC (US) | 2000-05-02 | — | — | US | claimed |
| EP-0804239-B1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1999-09-15 | — | — | EP | claimed |
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0804239-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | Riga, Dan (RO) | 1997-11-05 | — | — | EP | claimed |
| WO-1995033486-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1995-12-14 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250082598-A1 | Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease | NLS PHARMACEUTICS AG (CH) | 2025-03-13 | — | — | US | disclosed |
| US-20250082598-A1 | Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease | NLS PHARMACEUTICS AG (CH) | 2025-03-13 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4366722-A1 | MELAFENOXATE AND DERIVATIVES THEREOF FOR USE IN TREATING CIRCADIAN RHYTHM SLEEP DISORDERS WITH OR WITHOUT NEURODEGENERATIVE DISEASES | NLS Pharmaceutics AG (CH) | 2024-05-15 | — | — | EP | disclosed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230414452-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11806311-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| EP-4208155-A1 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149304-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145752-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230131450-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
| EP-4135712-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | Pike Therapeutics, Inc. (CA) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023281112-A1 | MELAFENOXATE AND DERIVATIVES THEREOF FOR USE IN TREATING CIRCADIAN RHYTHM SLEEP DISORDERS WITH OR WITHOUT NEURODEGENERATIVE DISEASES | NLS PHARMACEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |
| US-11541002-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220347117-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2022-11-03 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS INC (CA) | 2021-10-21 | — | — | US | disclosed |
| WO-2021209815-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS, INC. (CA) | 2021-10-21 | — | — | WO | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3846778-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | Aquestive Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| WO-2021097247-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210145731-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3811371-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | Aquestive Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200345624-A1 | Nanopore Delivery Device | HUDSON LEE EDWARD (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200101009-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-04-02 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| US-10369340-B2 | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | NANOMEDICAL SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-2419091-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3452597-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| CN-109462995-A | The method and composition of bioactivator | 波涛生命科学有限公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| CN-104546669-B | Nanochannel device and correlation technique | 得克萨斯大学体系董事会 | 2018-01-05 | — | — | CN | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319698-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2017-11-09 | — | — | US | disclosed |
| EP-3212167-A1 | GASTRORETENTIVE GEL FORMULATIONS | Jagotec AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-107106484-A | Gastric retention gel preparation | 雅戈泰克股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| US-9526824-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2355864-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| CN-105744983-A | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | 纳米医学系统公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20160175572-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3033138-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | Nanomedical Systems Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| CN-105687171-A | New application of aminoquinol | 昆明医科大学 | 2016-06-22 | — | — | CN | disclosed |
| US-20160171164-A1 | CONNECTED SYSTEMS, DEVICES, AND METHODS INCLUDING CANNABIS PROFILE MANAGEMENT | KINZER CRAIG E (US) | 2016-06-16 | — | — | US | disclosed |
| CN-105640955-A | Novel application of Aminoquinol | 昆明医科大学 | 2016-06-08 | — | — | CN | disclosed |
| WO-2016066256-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-9308162-B2 | Biocompatible oligomer-polymer compositions | TOLMAR THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160039591-A1 | PACKAGING SYSTEMS, DEVICES, METHODS, AND COMPOSITION INCLUDING CANNABINOID UNIT DOSE FORMS | KINZER CRAIG E (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038550-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH MEMORY LOSS | KINZER CRAIG E (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| WO-2015167760-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150246174-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912070-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | Celanese Acetate LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9096743-B2 | Process for forming films, fibers, and beads from chitinous biomass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104812777-A | Polysaccharide ester microspheres and methods and articles related thereto | CELANESE ACETATE LLC | 2015-07-29 | — | — | CN | disclosed |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | RESILIO COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| CN-104546669-A | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS | 2015-04-29 | — | — | CN | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9005185-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2015023557-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-2291174-B1 | FLOWABLE COMPOSITION COMPRISING BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS INC (US) | 2015-01-28 | — | — | EP | disclosed |
| CN-102271732-B | Nanochannel devices and related methods | UNIV TEXAS | 2014-12-31 | — | — | CN | disclosed |
| CN-104203220-A | Device and method for sustained release of therapeutic agent | UNIV TEXAS | 2014-12-10 | — | — | CN | disclosed |
| US-20140348936-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-27 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140328884-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140315720-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2790678-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2790677-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2770984-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140180251-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| CN-102333777-B | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2014-06-25 | — | — | CN | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014066463-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140113826-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2014031398-A1 | BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS | TICONA LLC (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140052264-A1 | Porous, Stabilized Craniomaxillofacial Implants and Methods and Kits Relating Thereto | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051771-A1 | Biomedical Devices Comprising Molded Polyethylene Components | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8632510-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | NUVO RESEARCH INC. (CA) | 2013-12-19 | — | — | US | disclosed |
| US-20130240483-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| CN-101815713-B | Polycyclic compounds | EISAI R&D MAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-103271083-A | Multi-functional ionic liquid compositions | UNIV ALABAMA | 2013-09-04 | — | — | CN | disclosed |
| US-8513304-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-08-20 | — | — | US | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-8480637-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013090891-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090893-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| CN-101326275-B | Multifunctional ionic liquid composition | UNIV ALABAMA | 2013-06-05 | — | — | CN | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130131628-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063004-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2181992-B1 | POLYCYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| EP-2559693-A1 | Polycyclic compound | Eisai R&D Management Co., Ltd. (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8314077-B2 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120115729-A1 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120095443-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-04-19 | — | — | US | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2419091-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2012-02-22 | — | — | EP | disclosed |
| CN-102333777-A | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2401276-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| EP-2355864-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7976871-B2 | Modified release composition of highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-07-12 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| EP-2291174-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | Tolmar Therapeutics, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| WO-2011001258-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES | EVITA LIFE SCIENCE PTE. LTD (SG) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010141470-A2 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010120817-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098488-A1 | ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| WO-2010056986-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009148581-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | QLT USA, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7199151-B2 | DHA-pharmaceutical agent conjugates of taxanes | LUITPOLD PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | disclosed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| EP-1466628-A1 | DHA-pharmaceutical agent conjugates | Luitpold Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | PROTARGA, INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | PROTARGA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-6602902-B2 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | PROTARGA, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030059471-A1 | Oral delivery formulation | COMPTON BRUCE JON (US) | 2003-03-27 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| EP-0870757-B1 | Fluoro-substituted adamantane derivatives | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| US-6174890-B1 | A SYNERGISTIC BIOLOGICAL, NEUROMETABOLIC AND CELLTROPHIC COMPOSITION COMPRISING ANTIOXIDATIVE AND -CATABOLIC STRESS (METHIONINE),-ANABOLIC DRUGS, VASODILATIVE AND NORMO-LIPIDEMIC DRUGS (NICOTINIC ACID), ENERGOACTIVE AND ANTITOXIC | RIGA DAN (RO) | 2001-01-16 | — | — | US | disclosed |
| US-6057364-A | USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS | PFIZER INC (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0804239-B1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0804239-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | Riga, Dan (RO) | 1997-11-05 | — | — | EP | disclosed |
| CN-1156410-A | Anti-stress, anti-injury and anti-aging medicine and production method thereof | RIGA D (RO) | 1997-08-06 | — | — | CN | disclosed |
| WO-1995033486-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995033486-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (37 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | EPHX2 2505/4885CYP1A2 2206/4885CYP3A4 1130/4885 |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | EPHX2 1078/4885CYP1A2 2793/4885CYP3A4 2379/4885 |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | PGRMC2, PGRMC1, CYP3A43 | EPHX2 1614/4885CYP1A2 33/4885CYP3A4 4/4885 |
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | EPHX2 2333/4885CYP1A2 4874/4885CYP3A4 4858/4885 |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | BMP2, CHERP, PUF60 | EPHX2 148/4885CYP1A2 355/4885CYP3A4 32/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | EPHX2 2505/4885CYP1A2 2206/4885CYP3A4 1130/4885 |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | EPHX2 71/4885CYP1A2 542/4885CYP3A4 751/4885 |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | EPHX2 292/4885CYP1A2 295/4885CYP3A4 1991/4885 |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | ADRA2C, ADRB3, ADRA2B | EPHX2 13/4885CYP1A2 55/4885CYP3A4 127/4885 |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | SI, TAS2R39, TAS2R31 | EPHX2 2389/4885CYP1A2 1539/4885CYP3A4 495/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | EPHX2 3498/4885CYP1A2 4806/4885CYP3A4 4614/4885 |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | EPHX2 181/4885CYP1A2 15/4885CYP3A4 25/4885 |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | EPHX2 1794/4885CYP1A2 4301/4885CYP3A4 4742/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | EPHX2 3116/4885CYP1A2 4494/4885CYP3A4 4865/4885 |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | OPRL1, OPRM1, HTR2A | EPHX2 1875/4885CYP1A2 1039/4885CYP3A4 2032/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | EPHX2 235/4885CYP1A2 662/4885CYP3A4 975/4885 |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | ALOX12, FABP2, ALOX15B | EPHX2 310/4885CYP1A2 305/4885CYP3A4 1041/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | EPHX2 2008/4885CYP1A2 3989/4885CYP3A4 4680/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | EPHX2 1373/4885CYP1A2 2013/4885CYP3A4 2335/4885 |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | BDNF, BACE1, GAP43 | EPHX2 3537/4885CYP1A2 3432/4885CYP3A4 4615/4885 |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | SMURF1, SMURF2, SMS | EPHX2 2605/4885CYP1A2 1180/4885CYP3A4 2160/4885 |
| US-20250082598-A1 | Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease | CRY1, PER2, MTNR1A | EPHX2 900/4885CYP1A2 118/4885CYP3A4 115/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | EPHX2 2031/4885CYP1A2 1313/4885CYP3A4 1585/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | EPHX2 1373/4885CYP1A2 2013/4885CYP3A4 2335/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | EPHX2 584/4885CYP1A2 262/4885CYP3A4 767/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | EPHX2 3439/4885CYP1A2 333/4885CYP3A4 143/4885 |
| US-20110028460-A1 | TOPICAL FORMULATION | SPTLC1, SPTSSB, SPTLC3 | EPHX2 3579/4885CYP1A2 2428/4885CYP3A4 2228/4885 |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | EPHX2 235/4885CYP1A2 662/4885CYP3A4 975/4885 |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | EPHX2 1805/4885CYP1A2 1695/4885CYP3A4 1285/4885 |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | SMURF1, SGMS1, SMURF2 | EPHX2 2957/4885CYP1A2 2610/4885CYP3A4 4121/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | EPHX2 144/4885CYP1A2 672/4885CYP3A4 2999/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | EPHX2 3619/4885CYP1A2 3184/4885CYP3A4 3867/4885 |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | OPRM1, OPRL1, OPRK1 | EPHX2 962/4885CYP1A2 1238/4885CYP3A4 1928/4885 |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | EPHX2 1733/4885CYP1A2 3777/4885CYP3A4 4589/4885 |
| US-20130079404-A1 | TOPICAL FORMULATION | SPTLC1, SPTLC3, SARAF | EPHX2 4079/4885CYP1A2 1890/4885CYP3A4 1441/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | EPHX2 2580/4885CYP1A2 4880/4885CYP3A4 4863/4885 |
| US-20120115729-A1 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | CHIA, CHIT1, CHI3L1 | EPHX2 3114/4885CYP1A2 2956/4885CYP3A4 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.